CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
It affects up to 10 per cent of women of reproductive age around the world
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
It is expanding the diagnostics business footprint in North East India
The plant is expected to start commercial operations from Q4FY24
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Cysoni is a bionic device that paces the heart with real-time respiratory modulation
Subscribe To Our Newsletter & Stay Updated
